SENORES PHARMACEUTICALS L (SENORES) - Total Assets
Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) holds total assets worth Rs16.04 Billion INR (≈ $173.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SENORES PHARMACEUTICALS L - Total Assets Trend (2022–2026)
This chart illustrates how SENORES PHARMACEUTICALS L's total assets have evolved over time, based on quarterly financial data. Also see SENORES PHARMACEUTICALS L market capitalisation for the company's overall valuation and market capitalisation.
SENORES PHARMACEUTICALS L - Asset Composition Analysis
Current Asset Composition (March 2026)
SENORES PHARMACEUTICALS L's total assets of Rs16.04 Billion consist of 50.7% current assets and 49.3% non-current assets. Review SENORES total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 2.8% |
| Accounts Receivable | Rs3.25 Billion | 20.3% |
| Inventory | Rs892.90 Million | 5.6% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs3.39 Billion | 21.1% |
| Goodwill | Rs465.50 Million | 2.9% |
Asset Composition Trend (2022–2026)
This chart illustrates how SENORES PHARMACEUTICALS L's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SENORES PHARMACEUTICALS L share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SENORES PHARMACEUTICALS L's current assets represent 50.7% of total assets in 2026, an increase from 45.7% in 2022.
- Cash Position: Cash and equivalents constituted 2.8% of total assets in 2026, down from 3.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 14.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 21.1% of total assets.
SENORES PHARMACEUTICALS L Competitors by Total Assets
Key competitors of SENORES PHARMACEUTICALS L based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
SENORES PHARMACEUTICALS L - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.92 | 0.04 | 1.01 |
| Quick Ratio | 1.71 | -0.20 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs3.88 Billion | Rs-2.32 Billion | Rs34.09 Million |
SENORES PHARMACEUTICALS L - Advanced Valuation Insights
This section examines the relationship between SENORES PHARMACEUTICALS L's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.62 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 10910.8% |
| Total Assets | Rs16.04 Billion |
| Market Capitalization | $698.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values SENORES PHARMACEUTICALS L's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SENORES PHARMACEUTICALS L's assets grew by 10910.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SENORES PHARMACEUTICALS L (2022–2026)
The table below shows the annual total assets of SENORES PHARMACEUTICALS L from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs16.04 Billion ≈ $173.45 Million |
+10910.80% |
| 2025-03-31 | Rs145.66 Million ≈ $1.58 Million |
-97.66% |
| 2024-03-31 | Rs6.22 Billion ≈ $67.25 Million |
+374.53% |
| 2023-03-31 | Rs1.31 Billion ≈ $14.17 Million |
+121.55% |
| 2022-03-31 | Rs591.52 Million ≈ $6.40 Million |
-- |
About SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more